About assembly biosciences - ASMB
Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. Its lead programs, ABI-5366 and ABI-1179, long-acting helicase-primase inhibitors, are in clinical development for recurrent genital herpes. The company is partnered with Gilead Sciences to advance current and future antiviral programs across herpesviruses, HBV, and HDV. Assembly Biosciences was founded in 2005 and is headquartered in South San Francisco, CA.
ASMB At a Glance
Assembly Biosciences, Inc.
Two Tower Place
South San Francisco, California 94080
| Phone | 1-833-509-4583 | Revenue | 72.30M | |
| Industry | Pharmaceuticals: Major | Net Income | -6,122,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 153.517% | |
| Fiscal Year-end | 12 / 2026 | Employees | 73 | |
| View SEC Filings |
ASMB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.273 |
| Price to Book Ratio | 2.608 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -11.328 |
| Enterprise Value to Sales | 1.878 |
| Total Debt to Enterprise Value | 0.019 |
ASMB Efficiency
| Revenue/Employee | 990,452.055 |
| Income Per Employee | -83,863.014 |
| Receivables Turnover | 29.225 |
| Total Asset Turnover | 0.382 |
ASMB Liquidity
| Current Ratio | 5.218 |
| Quick Ratio | 5.218 |
| Cash Ratio | 5.086 |
ASMB Profitability
| Gross Margin | 99.822 |
| Operating Margin | -16.76 |
| Pretax Margin | -8.467 |
| Net Margin | -8.467 |
| Return on Assets | -3.237 |
| Return on Equity | -5.099 |
| Return on Total Capital | -2.924 |
| Return on Invested Capital | -5.002 |
ASMB Capital Structure
| Total Debt to Total Equity | 1.271 |
| Total Debt to Total Capital | 1.255 |
| Total Debt to Total Assets | 1.017 |
| Long-Term Debt to Equity | 0.996 |
| Long-Term Debt to Total Capital | 0.983 |